Navigation Links
Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
Date:6/22/2013

atements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to up
'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
(Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 Developer ... camera on its Ponce City Market project in ... historic Sears, Roebuck & Company building into best-in-class office, ... completion, OxBlue reviewed Jamestown’s experience with their construction webcam ... , Jamestown wanted a construction camera ...
(Date:7/31/2014)... 31, 2014 Hoping to attract new customers ... trust , NutriGold is ready to ship out free ... make taking advantage of this offer fast and easy: ... and Development at NutriGold, "We know that every time customers ... their most precious asset: their own health or the health ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
(Date:7/31/2014)... Dr. Stewart Shofner of Shofner Vision ... in the United States to successfully treat glaucoma by performing ... device ever approved by the FDA. Dr. Shofner is ... of using a procedure known as Selective Laser Trabeculoplasty (SLT) ... colleagues now recognize that this procedure is a primary treatment ...
Breaking Medicine News(10 mins):Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4
... Inc. (OTC Bulletin Board: CARN) today said the ... be webcast live from the Kennedy I Room ... Healthcare Conference at New York City,s Palace Hotel ... The presentation will cover DelSite,s three key ...
... CAMBRIDGE, Mass., Nov. 5 Abt Associates has ... Office of Planning, Research,and Evaluation within the U.S. ... and Families (ACF) to lead a major evaluation,of ... and former recipients of Temporary Assistance for Needy ...
... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
... Relaxation in large, sound- and light-proof tanks with ... stress-related pain. This has been shown by Sven-ke ... with a dissertation from Karlstad University in Sweden. ... have indicated: sleep was improved, patients felt more ...
... may be more accurate than existing biological signposts ... into advanced forms of the disease. , ... edition of the International Journal of Cancer, the ... prevent patients from unnecessarily undergoing aggressive cancer treatments. ...
... /Xinhua-PRNewswire-FirstCall/ -- China Holdings, Inc.,(OTC Bulletin Board: ... its subsidiaries engage in multiple China-focused business ... real,estate, and pharmaceuticals, announced today the Company ... exclusive rights to develop and construct,the 2nd ...
Cached Medicine News:Health News:Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th 2Health News:Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:Floating effective for stress and pain 2Health News:Biomarker may be an early predictor of advanced breast cancer 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 3Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 4Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 5Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 6Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 7Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 8
... features including aspiration holes and additional ... procedures requiring precise dissection with decreased ... suction demands. ,Flexible design options ... nonretractable electrodes and multiple tip designs. ...
... Enhanced features including aspiration holes ... in laparoscopic procedures requiring precise dissection ... and increased suction demands. ,Flexible ... retractable and nonretractable electrodes and multiple ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: